Literature DB >> 28821400

Alzheimer's disease as oligomeropathy.

Kenjiro Ono1.   

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and is characterized by pathological aggregates of amyloid β-protein (Aβ) and tau protein. On the basis of genetic evidence, biochemical data, and animal models, Aβ has been suggested to be responsible for the pathogenesis of AD (the amyloid hypothesis). Aβ molecules tend to aggregate to form oligomers, protofibrils, and mature fibrils. Although mature fibrils in the final stage have been thought to be the cause of AD pathogenesis, recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models, and human samples, such as cerebrospinal fluids and postmortem brains of AD patients, suggest that pre-fibrillar forms (oligomers of Aβ) are more deleterious than are extracellular fibril forms. Based on this recent evidence showing that oligomers have a central role in the pathogenesis of AD, the term "oligomeropathy" could be used to define AD and other protein-misfolding diseases. In this review, I discuss recent developments in the "oligomer hypothesis" including our research findings regarding the pathogenesis of AD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β-protein; Oligomeropathy; Oligomers

Mesh:

Substances:

Year:  2017        PMID: 28821400     DOI: 10.1016/j.neuint.2017.08.010

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  29 in total

1.  Silencing of LRP1 Exacerbates Inflammatory Response Via TLR4/NF-κB/MAPKs Signaling Pathways in APP/PS1 Transgenic Mice.

Authors:  Yingying He; John Bosco Ruganzu; Quzhao Zheng; Xiangyuan Wu; Hui Jin; Xiaoqian Peng; Bo Ding; Chengheng Lin; Shengfeng Ji; Yanbing Ma; Weina Yang
Journal:  Mol Neurobiol       Date:  2020-06-22       Impact factor: 5.590

2.  The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity.

Authors:  Julia Ring; Jelena Tadic; Selena Ristic; Michael Poglitsch; Martina Bergmann; Nemanja Radic; Dirk Mossmann; YongTian Liang; Marta Maglione; Andrea Jerkovic; Roozbeh Hajiraissi; Marcel Hanke; Victoria Küttner; Heimo Wolinski; Andreas Zimmermann; Lana Domuz Trifunović; Leonie Mikolasch; Daiana N Moretti; Filomena Broeskamp; Julia Westermayer; Claudia Abraham; Simon Schauer; Christopher Dammbrueck; Sebastian J Hofer; Mahmoud Abdellatif; Guido Grundmeier; Guido Kroemer; Ralf J Braun; Niklas Hansen; Cornelia Sommer; Mirjana Ninkovic; Sandra Seba; Patrick Rockenfeller; Friederike-Nora Vögtle; Jörn Dengjel; Chris Meisinger; Adrian Keller; Stephan J Sigrist; Tobias Eisenberg; Frank Madeo
Journal:  EMBO Mol Med       Date:  2022-04-04       Impact factor: 14.260

3.  Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.

Authors:  Men Su; Kambiz Naderi; Nathalie Samson; Ihsen Youssef; Livia Fülöp; Zsolt Bozso; Serge Laroche; Benoit Delatour; Sabrina Davis
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

4.  Chrysophanol improves memory ability of d-galactose and Aβ25-35 treated rat correlating with inhibiting tau hyperphosphorylation and the CaM-CaMKIV signal pathway in hippocampus.

Authors:  Ting Ye; Xinquan Li; Peng Zhou; Shu Ye; Huawu Gao; Rupeng Hua; Junlong Ma; Yan Wang; Biao Cai
Journal:  3 Biotech       Date:  2020-02-13       Impact factor: 2.406

5.  Pine Bark Polyphenolic Extract Attenuates Amyloid-β and Tau Misfolding in a Model System of Alzheimer's Disease Neuropathology.

Authors:  Kenjiro Ono; Danyue Zhao; Qingli Wu; James Simon; Jun Wang; Aurelian Radu; Giulio Maria Pasinetti
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy.

Authors:  Yukiko Mori; Mayumi Tsuji; Tatsunori Oguchi; Kensaku Kasuga; Atsushi Kimura; Akinori Futamura; Azusa Sugimoto; Hideyo Kasai; Takeshi Kuroda; Satoshi Yano; Sotaro Hieda; Yuji Kiuchi; Takeshi Ikeuchi; Kenjiro Ono
Journal:  Front Neurol       Date:  2021-04-23       Impact factor: 4.003

7.  Transmission of Cerebral β-Amyloidosis Among Individuals.

Authors:  Tsuyoshi Hamaguchi; Kenjiro Ono; Masahito Yamada
Journal:  Neurochem Res       Date:  2022-03-11       Impact factor: 4.414

8.  Deletion of plasma Phospholipid Transfer Protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-β deposition in the J20 mouse model of Alzheimer's disease.

Authors:  Marine Mansuy; Stella Baille; Geoffrey Canet; Amélie Borie; Catherine Cohen-Solal; Michel Vignes; Véronique Perrier; Nathalie Chevallier; Naig Le Guern; Valérie Deckert; Laurent Lagrost; Laurent Givalois; Catherine Desrumaux
Journal:  Oncotarget       Date:  2018-04-13

9.  Rationally Designed Antibodies as Research Tools to Study the Structure-Toxicity Relationship of Amyloid-β Oligomers.

Authors:  Ryan Limbocker; Benedetta Mannini; Rodrigo Cataldi; Shianne Chhangur; Aidan K Wright; Ryan P Kreiser; J Alex Albright; Sean Chia; Johnny Habchi; Pietro Sormanni; Janet R Kumita; Francesco S Ruggeri; Christopher M Dobson; Fabrizio Chiti; Francesco A Aprile; Michele Vendruscolo
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

Review 10.  BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.

Authors:  Gerald Koelsch
Journal:  Molecules       Date:  2017-10-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.